Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hospira's Epogen Biosimilar Appears Poised For Quick Advisory Cmte. OK

May 24 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Apr 22 2017

Pending Biosimilars

Feb 13 2017

Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions

Jan 24 2017

Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?

Jul 20 2016

Related Companies

Hospira, Inc.

Amgen, Inc.

Pfizer Inc.

Samsung Bioepis Co., Ltd.

Johnson & Johnson

Puma Biotechnology, Inc.

Emmaus Life Sciences, Inc.

Additional Topics

United States Advisory Committees Biosimilars Regulation FDA BioPharmaceutical Cancer

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window